Biological materials related to c-met
AssigneeAblynx N.V.
InventorsGerald Beste, Guy Hermans, Soren Steffensen, Alexander Szyroki, Cedric Jozef Neotere Ververken, Tinneke Denayer
Life of this patent
Estimating the term…
Abstract
The present invention relates to biological materials related to c-Met possibly in combination with VEGF and/or EGFR, and more in particular to polypeptides, nucleic acids encoding such polypeptides; to methods for preparing such polypeptides; to host cells expressing or capable of expressing such polypeptides; to compositions and in particular to pharmaceutical compositions that comprise such polypeptides, for prophylactic, therapeutic or diagnostic purposes. Methods and kits for assessing the responsiveness of a patient to c-Met therapy are also described and provided.
Claims24
An immunoglobulin single variable domain that can displace HGF from human c-Met (SEQ ID NO:
- 1) with an IC50 of less than 10 nM and a maximal HGF displacement level of 60% to 80% or more.
Method for screening immunoglobulin single variable domains directed against c-Met and in particular human c-Met (SEQ ID NO:
- 1) that comprises at least the steps of:
- a) providing a set, collection or library of VHH1 type immunoglobulin single variable domains;
- and
- b) screening said set, collection or library of VHH1 type immunoglobulin single variable domains for immunoglobulin single variable domains that can bind to and/or have affinity for c-Met and in particular human c-Met (SEQ ID NO:
- 1);
- and
- c) isolating the amino acid sequence(s) that can bind to and/or have affinity for c-Met and in particular human c-Met (SEQ ID NO:
- 1).
An in vitro method for assessing the responsiveness of a patient suffering from a c-Met associated disease or disorder to a therapy, said method comprising the steps of:
- a) providing from said patient a first sample prior to therapy and measuring the amount of soluble c-Met in said first sample,
- b) providing from said patient a second sample post initiation of therapy and measuring the amount of soluble c-Met in said second sample,
- c) comparing the amount of soluble c-Met present in the first sample to the amount of soluble c-Met found in the second sample;
- wherein a decrease in the amount of soluble c-Met found in the second sample compared to the amount of soluble c-Met in the first sample indicates that the patient is responsive to said therapy.
Dependencies are inferred from the claim text.